caa a22 4500 477035221 CHVBK 20180405111303.0 cr unu---uuuuu 170330e19960701xx s 000 0 eng 10.1007/s002689900134 doi (NATIONALLICENCE)springer-10.1007/s002689900134 Islet Cell Carcinoma of the Pancreas [Elektronische Daten] [Chung Yau Lo, Jon A. van Heerden, Geoffrey B. Thompson, Clive S. Grant, Jon Arne Söreide, William S. Harmsen] Abstract. Islet cell carcinoma (ICC) of the pancreas is a rare, indolent malignancy associated with higher resectability rate and better survival than ductal carcinoma. This retrospective study presents results of surgical treatment from a single institution. From 1985 through 1993 a total of 64 patients (36 men, 28 women) were surgically treated for ICC. Ages ranged from 22 to 80 years (median 55 years) with a median postoperative follow-up of 39 months (range 10-97 months). Of the 64 patients, 30 (47%) had functioning and 34 (53%) nonfunctioning tumors. Gastrinoma (: n = 11) followed by glucagonoma ( n = 6) and insulinoma ( n = 4) were the most common functioning tumors. In the patients undergoing a laboratory study, 67% of the nonfunctioning tumors had elevated peptide hormone levels. Potentially curative resections were performed in 17 patients (26%), palliative procedures in 35 (55%), and exploratory laparotomy alone in 12 (19%). One patient (2%) died within 30 days after operation. Symptomatic improvement was achieved in 96% of patients with a mean duration of 22 months. Three- and five-year survivals were 66% and 49%, respectively. In patients with curative resection, the disease-free survival at 3 years was 53% (95% CI: 32-86%). The presence of diffuse hepatic metastases was a predictor of poor survival at 3 years (74% versus 58%; p = 0.05); there was no statistically significant difference in survival between functioning and nonfunctioning groups ( p > 0.1). Although curative resection for ICC is rare, meaningful palliation can be achieved in most patients with rare mortality and acceptable morbidity. 1996 by the Société Internationale de Chir, ugie Lo Chung Yau Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, U.S.A., US aut van Heerden Jon A. Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, U.S.A., US aut Thompson Geoffrey B. Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, U.S.A., US aut Grant Clive S. Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, U.S.A., US aut Söreide Jon Arne Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, U.S.A., US aut Harmsen William S. Section of Biostatistics, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, Minnesota 55905, U.S.A., US aut https://doi.org/10.1007/s002689900134 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002689900134 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lo Chung Yau Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, U.S.A., US aut NATIONALLICENCE 700 1- van Heerden Jon A. Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, U.S.A., US aut NATIONALLICENCE 700 1- Thompson Geoffrey B. Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, U.S.A., US aut NATIONALLICENCE 700 1- Grant Clive S. Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, U.S.A., US aut NATIONALLICENCE 700 1- Söreide Jon Arne Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, U.S.A., US aut NATIONALLICENCE 700 1- Harmsen William S. Section of Biostatistics, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, Minnesota 55905, U.S.A., US aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer